|
|||||
|
|
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial |
|
| Authors: | Stefan D. Anker Javed Butler Gerasimos S. Filippatos Waheed Jamal Afshin Salsali Janet Schnee Karen Kimura Cordula Zeller Jyothis George Martina Brueckmann Faiez Zannad Milton Packer |
| Abstract: | |
| Keywords: | Heart failure Diabetes SGLT2 inhibitors Trial design |